A Clinical Trial to Assess PVX7 Immunotherapy Regimens in Advanced Cervical Cancer Patients

Johns Hopkins Medicine

Status and phase: Not yet enrolling; Phase 1

Conditions: Cervical Cancer

Treatments: Drug: PVX7

Study type: Interventional

Funder types: Other; NIH

Identifiers

NCT06315257

IRB00388854 (Other Identifier)

J23105sIRB

Details and patient eligibility

About

A Feasibility Trial of PVX7 vaccine in advanced cervical cancer patients who have completed primary definitive therapy.

Full description

A Feasibility Trial of PVX7 in advanced cervical cancer patients who have completed primary definitive therapy.

• Safety and immunogenicity study
• Patients are randomized in a 1:1 ratio to two cohorts, up to 16 patients in each of intramuscular or skin scarification vaccine injection, up to 32 patients total
• Human Immunodeficiency Virus (HIV)-negative patients only
• Treatment dose: Arm A: pBI-11 DNA (3 mg) twice via intramuscular (IM) injection, followed by one dose of TA-HPV (2.5x105 pfu) via skin scarification; Arm B: pBI-11 DNA (3 mg) twice, followed by one dose of TA-HPV (107 pfu) via IM injection
• Schedule for administration: PVX7 vaccination at weeks 1, 5, and 9
• Follow-up for 2 years per standard of care (SoC)

Enrollment: 32 estimated patients

Sex: Female

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Female subjects age 18 years or older with diagnosis of advanced cervical cancer and have completed primary treatment within the past 12 months.
• No history of or current evidence of residual disease or disease recurrence based on imaging and clinical assessments within 8 weeks of enrollment
• HIV uninfected
• Hepatitis B surface antigen negative
• Anti-hepatitis C (HCV) antibody negative or negative HCV polymerase chain reaction (PCR)
• Patients who are able and willing to comply with all study procedures and voluntarily sign an informed consent form
• Adequate organ function as defined by the following parameters:
• white blood cell count ≥ 3,000
• lymphocyte number ≥ 500
• absolute neutrophil count ≥ 1,000
• platelets ≥ 90,000
• hemoglobin ≥ 9
• total bilirubin <1.5 X upper limit of normal (ULN), <3 x ULN if Gilbert's disease
• Aspartate Transferase(AST)/Alanine Transaminase (ALT) <3 X ULN
• creatinine < 1.5 X ULN or estimated creatinine clearance ≥ 60 ml/min per Modified Cockcroft-Gault Formula
• Eastern Cooperative Oncology Group performance status of 0 or 1
• All clinically significant toxicities related to prior therapy should be less than or equal to Grade 1 at time of enrollment
• Ability and willingness for one month post vaccination to follow vaccine inoculation site care and avoid close social contact with children under 1 year old or close social or domestic contact with a pregnant woman or individuals at high risk of serious adverse effects of vaccinia virus, for instance, those with past or present eczema, or immunodeficiency states including HIV infection

Exclusion criteria

• Women of child-bearing potential (i.e., those who have had fertility-sparing procedures for the management of cervical cancer) will be excluded unless agreed to remain sexually abstinent or have a partner who is sterile (i.e. vasectomy), or use methods of contraception (e.g., oral contraception, barrier methods, spermicide, intrauterine device (IUD)), throughout the first 6 months of the study.
• Because there is a risk for adverse events in nursing infants, breastfeeding must be discontinued if the mother is treated on study.
• Diagnosed with a recognized immunodeficiency disease including cellular immunodeficiencies, hypogammaglobulinemia or dysgammaglobulinemia; patients diagnosed with acquired, hereditary, or congenital immunodeficiencies
• Diagnosis with a medical condition that requires systemic treatment with immunosuppressive drugs such as cyclosporine, adrenocorticotropic hormone (ACTH), alkylating agents, antimetabolites, radiation, Tumor Necrosis Factor (TNF) inhibitors, or systemic corticosteroids, either chronically or within 30 days of first PVX7 vaccination.
• Administration of any blood product within 30 days of signing informed consent.
• Need for ongoing therapeutic anticoagulation during the study period due to concern for increased risk of bleeding.
• Previous severe allergic reaction or hypersensitivity to a vaccine or any of its components
• Participation in a study with an investigational compound or device within 30 days of signing informed consent
• History of seizures (unless seizure free for 5 years)
• Known active central nervous system disease
• Surgery within 30 days of first PVX7 vaccination, excluding minor procedures
• Diagnosis with an uncontrolled intercurrent illness including, but not limited to, ongoing, or active infection, or psychiatric illness/social situations that would limit compliance with study requirements
• Diagnosis with an active autoimmune disease (e.g., rheumatoid arthritis, systemic lupus erythematosus (SLE), ulcerative colitis, Crohn's Disease, multiple sclerosis (MS), ankylosing spondylitis)
• History of myocarditis or pericarditis.
• Known underlying heart disease (e.g., cardiomyopathy, congestive heart failure, symptomatic arrhythmia not controlled by medication, unstable angina, history of acute myocardial infarction or cerebrovascular accident within the past 6 months).
• Patients and the patients close social, sexual, or domestic contacts may not have non-healed wounds or active exfoliative skin conditions such as: Eczema, Burns, Impetigo, Varicella-zoster virus infection, Herpes simplex virus infection, Severe acne, Severe diaper dermatitis with extensive areas of denuded skin, Psoriasis, Lichen planus, Darier disease (keratosis follicularis).
• History or presence of atopic dermatitis
• Inability or unwillingness to for one month post vaccination follow vaccine inoculation site care and avoid social contact with children under 1 year old or close social or domestic contact with a pregnant woman or individuals at high risk of serious adverse effects of vaccinia virus, for instance, those with past or present eczema, or immunodeficiency states including HIV infection

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

32 participants in 2 patient groups

pBI-11 DNA plus TA-HPV via Skin Scarification

Experimental group

Description:

Participants will receive pBI-11 DNA and TA-HPV via Skin Scarification

Treatment:

Drug: PVX7

pBI-11 DNA plus TA-HPV via IM Injection

Experimental group

Description:

Participants will receive pBI-11 DNA and TA-HPV via IM Injection

Treatment:

Drug: PVX7